NCT01721967已完成4 期
Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Drug Tolerability
研究概览
简要总结
The purpose of RHYME is to evaluate the safety and efficacy of ranolazine in Hypertrophic Cardiomypathy patients with chest pain or dyspnea despite treatment with standard medical therapy. This is a small, pilot, open-label (non-randomized) study of an approved drug for the treatment of angina in a novel patient population (adult patient population with hypertrophic cardiomyopathy).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older
- •Left Ventricle wall thickness >/= 15mm in the absence of other condition causing hypertrophy
- •Baseline Angina/Shortness of Breath Frequency of > 2 episodes per week
- •Willing to provide informed consent
排除标准
- •Severe stenotic valvular disease
- •Severe valvular regurgitation except mitral regurgitation due to systolic anterior motion
- •Significant (>60% stenosis) coronary artery disease
- •Acute coronary syndrome within 30 days
- •Severe heart failure defined as LV systolic dysfunction with Ejection Fraction <40% or NYHA class 4 symptoms
- •Severe renal impairment (glomerular filtration rate, <30 mL/min/1.73 m2)
- •Moderate-severe hepatic impairment (Child-Pugh classes B and C)
- •Hospitalization for cardiac reason within 3 months of enrollment
- •Anticipated changes to treatment of HCM within study period, including medications, device implantation, or septal reduction therapies
- •Concomitant use of ketoconazole, macrolide antibiotics, and HIV protease inhibitors
- •Active myocarditis, pericarditis, or restrictive cardiomyopathy
- •Non-cardiac terminal illness with expected survival less than 6 months
- •Women who are of childbearing potential
- •Inability to perform or adhere to study protocol
研究组 & 干预措施
Ranolazine
Experimental
Ranolazine, 500 mg for 60 days
干预措施: Ranolazine (Drug)
结局指标
主要结局
Drug Tolerability
时间窗: 60 days
Total number of patients that tolerated 1,000mg BID dose and 500 mg BID dose
Number of Adverse Events Considered Probably or Possibly Related to Study Drug
时间窗: 60 Days
Number of events that are considered probably or possibly related to study drug.
QT Interval
时间窗: 60 Days
次要结局
- Seattle Angina Questionnaire (SAQ)(60 Days post treatment)
- Kansas City Cardiomyopathy Questionnaire (KCCQ)(60 days post treatement)
- Improvement in Number of Episodes of Angina Per Week(Baseline and 60 Days post treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Ranolazine and Pulmonary HypertensionAnginaPulmonary Arterial HypertensionNCT01174173Northwestern University11
已完成
3 期
Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV DysfunctionVentricular ArrythmiasSudden Cardiac DeathNCT00998218Aspirus Heart and Vascular Institute-Research and Education7
终止
不适用
Effect of Ranolazine on Echocardiographic Indices of Diastolic DysfunctionRanolazineTissue Doppler UltrasoundEchocardiographyDiastolic Heart FailureNCT00574756University of California, San Diego14
已完成
不适用
Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial IschemiaMicrovascular Coronary Dysfunction (MCD)NCT01342029Cedars-Sinai Medical Center142
已完成
4 期
Ranolazine and Microvascular Angina by PET in the Emergency DepartmentMicrovascular AnginaNCT02052011Yale University31